GLP-1 Cost and Insurance Coverage: How to Actually Get These Drugs Covered

If you've tried to fill a Wegovy or Zepbound prescription and seen a $1,400 sticker, you're not alone. The list prices are extraordinary. The actual costs you pay depend on insurance, savings programs, manufacturer cash-pay options, and a fair amount of administrative effort.

List prices (April 2026)

Approximate U.S. list prices per month:

Wegovy (semaglutide for weight): ~$1,350
Ozempic (semaglutide for diabetes): ~$1,000
Zepbound (tirzepatide for weight): ~$1,060
Mounjaro (tirzepatide for diabetes): ~$1,070
Saxenda (liraglutide for weight): ~$1,400
Victoza (liraglutide for diabetes): ~$815

These are list prices. Almost no one pays them in full.

Insurance coverage — diabetes vs weight loss

Coverage usually splits along the FDA-approved indication:

Diabetes (Ozempic, Mounjaro, Victoza):

Often covered by most insurance for type 2 diabetes
Step therapy may apply (try metformin first)
Some plans require prior auth even for diabetes

Weight management (Wegovy, Zepbound, Saxenda):

Covered by some insurance, not most
Usually requires BMI ≥30 (or ≥27 with comorbidity)
Prior authorization is the rule
Documentation of prior weight loss attempts often required
Periodic re-authorization (12-month renewals)

Medicare:

Does NOT currently cover GLP-1 specifically for weight loss (this may change)
Covers Ozempic and Mounjaro for diabetes
Covers Wegovy specifically for cardiovascular event reduction in patients with established CVD (a 2024 expansion)

Medicaid:

Coverage varies wildly by state
Many state Medicaid programs do not cover weight-loss indications
Better coverage for diabetes indications

Manufacturer direct-pay programs

If your insurance won't cover, the manufacturer cash-pay programs are usually your best bet:

LillyDirect (Zepbound, Mounjaro):

Self-pay program with significant discounts
Zepbound vials (single-dose): ~$400–500/month at lower doses
Direct shipping
Eligible without insurance approval

NovoCare (Wegovy):

Similar self-pay program
Various dose-strength savings
Roughly $500–650/month for self-pay

Savings cards (for insured patients):

Manufacturer cards can reduce copays significantly
Wegovy savings card can bring copays to as low as $0–25/month for eligible patients with commercial insurance
Mounjaro/Zepbound savings card similar
Eligibility usually excludes Medicare/Medicaid patients

Strategies to get coverage

If your insurance denies:

1. Appeal. Many denials are reversed on appeal with proper documentation. Your prescriber's office should help.

2. Document comorbidities. Type 2 diabetes, sleep apnea, hypertension, hyperlipidemia, fatty liver — these support medical necessity.

3. Document prior attempts. Weight Watchers, Noom, prior medications, behavioral programs. Show that lifestyle alone hasn't worked.

4. Switch indication products. If you have type 2 diabetes alongside obesity, Ozempic or Mounjaro may be covered while Wegovy or Zepbound isn't.

5. Try a less-restricted alternative. Saxenda is sometimes covered when Wegovy isn't.

6. Ask about pharmacy benefit alternatives. Some plans have specialty pharmacies with different formularies.

7. Use a patient assistance program. Both Lilly and Novo Nordisk have programs for low-income patients.

What about compounded?

Compounded semaglutide and tirzepatide were widely available and inexpensive ($150–400/month) during the FDA shortage period (2023–2024). As supplies have stabilized, the FDA has restricted compounding.

Risks (covered in detail in our compounded GLP-1 guide):

Variable purity
Counterfeits in the gray market
No standardized FDA review

If brand-name is unaffordable and compounded is your only option, vet the pharmacy carefully.

What about international/online?

Some patients import medication from Canada, Mexico, or other countries. Legal status varies. Personal-use importation has historically been tolerated but exists in a gray area. Quality varies. Caution warranted.

Telehealth pharmacy services proliferated in 2023–2024. Some are legitimate; some prescribe with minimal oversight. Look for ones with real medical evaluation, not "fill out a form, get a script."

Cost comparison summary

For a typical patient targeting effective weight loss:

Best case: Insurance covers, copay $25–100/month
Mid case: Manufacturer cash pay, $400–650/month
High case: Out-of-pocket retail, $1,000–1,400/month
Compounded (with caveats): $200–500/month
No medication (lifestyle only): $0 + likely much smaller weight loss

When to push, when to accept

Push hard for coverage if:

You have a labeled indication and insurance is being inflexible
You have multiple comorbidities
Your prescriber strongly supports the medication

Accept and pivot if:

Multiple appeals have failed
Cash-pay through manufacturer is workable for your budget
A different drug is covered that may also work for you
You're a candidate for less-aggressive intervention (lifestyle + a non-GLP-1 weight medication)

What's coming

Several things may change the cost landscape:

Generic semaglutide could enter the market starting around 2026 (varies by jurisdiction)
Generic liraglutide is expected to be more widely available
Negotiated Medicare prices under the Inflation Reduction Act may include some GLP-1s
More commercial competition as new triple agonists arrive

The cost picture in 2027 may look meaningfully different from today.

Bottom line

GLP-1 medications are expensive but increasingly accessible. Insurance coverage is the first option (BMI documentation, prior auth, appeals if denied). Manufacturer direct-pay programs are the second option (LillyDirect, NovoCare). Savings cards help insured patients with high copays. Compounded is a last-resort option with real safety caveats. Don't assume the sticker price is what you'll pay — work the system.